Molsidomine
Who holds supplier records for Molsidomine? 2 organisations hold a current record for Molsidomine: an active US FDA Type II Drug Master File or a CEP. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: Germany (1) and Poland (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Molsidomine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/molsidomine
Reading the evidence
- 2 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 2 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (2)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Molsidomine. Country is the organisation's recorded country, not necessarily the manufacturing site.
- GermanyCEP Company GMP cert on record
- PolandCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (2)
Certificates of Suitability on the EDQM register for Molsidomine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| ZAKŁADY FARMACEUTYCZNE POLPHARMA S.A. Starogard Gdański | PL | CEP 2017-021 - Rev 01 Molsidomine | Mar 2024 | Inspected Jul 2026 Poland |
| ALLESSA GMBH FRANKFURT | DE | CEP 2017-214 - Rev 01 Molsidomine | Jan 2024 | Inspected Mar 2024 Germany |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Overview
Molsidomine is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1329455).
Chemical identity
- IUPAC name
- 1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
- Canonical SMILES
- CCOC(=NC1=C[N+](=NO1)N2CCOCC2)[O-]
- InChIKey
- XLFWDASMENKTKL-UHFFFAOYSA-N
- Synonyms
- CAS 276, CAS-276, CAS276, Corvasal, Corvaton mite, Corvaton ret, Molsidomina, Molsidomine, Morsydomine, NSC-757398, SIN-10, SIN-10;Morsydomine
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Vasodilator
- Physiologic effect
- Vasodilation
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Molsidomine?
2 organisations hold an active US FDA Type II Drug Master File or a CEP for Molsidomine: Allessa Gmbh (Germany) and Zakłady Farmaceutyczne Polpharma S.A. (Poland). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Does Molsidomine have a European Certificate of Suitability?
Yes. 2 organisations hold a valid CEP for Molsidomine on the EDQM register, including ZAKŁADY FARMACEUTYCZNE POLPHARMA S.A. Starogard Gdański (PL) and ALLESSA GMBH FRANKFURT (DE). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Molsidomine supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Molsidomine?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.